Healthcare provider profile · identity verified

John Peter Carradini, MD

Internal Medicine · TULSA, OK · NPI 1285262014

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	213	98
Atorvastatin Calcium	Atorvastatin Calcium	192	87
Amlodipine Besylate	Amlodipine Besylate	184	88
Levothyroxine Sodium	Levothyroxine Sodium	149	70
Gabapentin	Gabapentin	142	54
Trazodone Hcl	Trazodone Hcl	135	55
Losartan Potassium	Losartan Potassium	126	60
Lisinopril	Lisinopril	123	51
Metformin Hcl	Metformin Hcl	111	48
Omeprazole	Omeprazole	110	45
Metoprolol Succinate	Metoprolol Succinate	100	47
Furosemide	Furosemide	96	41
Duloxetine Hcl	Duloxetine Hcl	93	35
Pantoprazole Sodium	Pantoprazole Sodium	87	40
Spironolactone	Spironolactone	86	36
Carvedilol	Carvedilol	84	32
Tamsulosin Hcl	Tamsulosin Hcl	84	32
Albuterol Sulfate Hfa	Albuterol Sulfate	83	38
Pregabalin	Pregabalin	82	25
Fluticasone Propionate	Fluticasone Propionate	75	34
Metformin Hcl Er	Metformin Hcl	73	28
Ozempic	Semaglutide	72	28
Sertraline Hcl	Sertraline Hcl	72	20
Baclofen	Baclofen	68	20
Mounjaro	Tirzepatide	67	19
Zolpidem Tartrate	Zolpidem Tartrate	67	20
Eliquis	Apixaban	65	21
Alprazolam	Alprazolam	63	18
Potassium Chloride	Potassium Chloride	63	26
Escitalopram Oxalate	Escitalopram Oxalate	61	24
Meloxicam	Meloxicam	60	22
Pravastatin Sodium	Pravastatin Sodium	60	21
Fluoxetine Hcl	Fluoxetine Hcl	59	23
Pioglitazone Hcl	Pioglitazone Hcl	58	22
Allopurinol	Allopurinol	55	23
Jardiance	Empagliflozin	55	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	20
Bupropion Xl	Bupropion Hcl	53	23
Montelukast Sodium	Montelukast Sodium	53	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	32
Metoprolol Tartrate	Metoprolol Tartrate	52	21
Tramadol Hcl	Tramadol Hcl	52	22
Hydroxyzine Hcl	Hydroxyzine Hcl	50	21
Diclofenac Sodium	Diclofenac Sodium	48	25
Prednisone	Prednisone	47	39
Alendronate Sodium	Alendronate Sodium	46	15
Venlafaxine Hcl Er	Venlafaxine Hcl	46	17
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	45	14
Citalopram Hbr	Citalopram Hydrobromide	44	16
Donepezil Hcl	Donepezil Hcl	41	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	40	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	16
Buspirone Hcl	Buspirone Hcl	37	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	25
Hydrochlorothiazide	Hydrochlorothiazide	32	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	30	25
Spiriva Respimat	Tiotropium Bromide	30	suppressed
Valsartan	Valsartan	29	11
Mirtazapine	Mirtazapine	28	11
Simvastatin	Simvastatin	28	12
Famotidine	Famotidine	27	suppressed
Glipizide Er	Glipizide	27	12
Ezetimibe	Ezetimibe	26	11
Farxiga	Dapagliflozin Propanediol	26	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	suppressed
Diazepam	Diazepam	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Ondansetron Odt	Ondansetron	25	16
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	24	suppressed
Clonazepam	Clonazepam	24	suppressed
Fluconazole	Fluconazole	24	13
Telmisartan	Telmisartan	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	12
Olmesartan Medoxomil	Olmesartan Medoxomil	23	suppressed
Lamotrigine	Lamotrigine	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	11
Topiramate	Topiramate	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Celecoxib	Celecoxib	19	suppressed
Ibuprofen	Ibuprofen	19	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	16
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Torsemide	Torsemide	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Atenolol	Atenolol	16	11
Doxycycline Hyclate	Doxycycline Hyclate	16	13
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	15	suppressed
Estradiol	Estradiol	15	suppressed
Levofloxacin	Levofloxacin	15	14
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Finasteride	Finasteride	14	suppressed
Glipizide	Glipizide	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Trulicity	Dulaglutide	14	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Linzess	Linaclotide	13	suppressed
Colchicine	Colchicine	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Gemtesa	Vibegron	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error